Transcript of Earnings Call with Analyst / Investor on Unaudited Financial Results for the first quarter and three months ended June 30, 2026

August 10, 2026 To, To, Listing Operation Department Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Bandra Kurla Dalal Street, Mumbai-400001 Complex, Bandra (East), Mumbai-400051 (Scrip Code: 544644) (SYMBOL: CORONA) Dear Sir / Madam, Sub.: Transcript of Earnings Conference call with Analyst / Investor on Financial Results for the first quarter and three months ended June 30, 2026 Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Transcript of the Earnings Conference call (i.e. post earnings/quarterly call) which was held on August 03, 2026 at 11:30 a.m. (IST) for the first quarter and three months ended June 30, 2026. The said transcript is also available on the website of the Company at www.coronaremedies.com You are requested to take note of the above. Thanking you. Yours faithfully, For CORONA Remedies Limited Chetna Dharajiya Company Secretary and Compliance Officer Encl.: A/a “CORONA Remedies Limited Q1 FY27 Earnings Conference Call” August 03, 2026 E&OE - This transcript is edited for factual errors. In case of discrepancy, the audio recording uploaded on the stock exchanges on 3rd August 2026 will prevail MANAGEMENT: MR. NIRAV MEHTA – MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER – CORONA REMEDIES LIMITED MR. ANKUR MEHTA – JOINT MANAGING DIRECTOR – CORONA REMEDIES LIMITED MR. BHAVIN BHAGAT – CHIEF FINANCIAL OFFICER – CORONA REMEDIES LIMITED MODERATOR: MR. MAULIK VARIA – 360 ONE CAPITAL Page 1 of 17 CORONA Remedies Limited August 03, 2026 Moderator: Ladies and gentlemen, good day, and welcome to Q1 FY27 Earnings Conference Call of CORONA Remedies Limited. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star, then zero on your touch-tone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Maulik Varia from 360 One Capital. Thank you, and over to you, sir. Maulik Varia: Hi, thank you. Good morning, everyone. On behalf of 360 One Capital, we welcome you all on Q1 FY27 earnings conference call of CORONA Remedies Limited. Today on the call, we are joined by Mr. Nirav Mehta, Managing Director and CEO; Mr. Ankur Mehta, Joint Managing Director; and Mr. Bhavin Bhagat, Chief Financial Officer at CORONA Remedies Limited. We will begin the call with opening remarks from the management followed by a Q&A session. Thank you, and over to you, Nirav sir. Nirav Mehta: Good morning, ladies and gentlemen. Thank you all for joining us on quarter 1 FY27 earnings conference call for CORONA Remedies Limited. Along with me on the call, I am joined by our Joint Managing Director, Mr. Ankur Mehta; our Chief Financial Officer, Mr. Bhavin Bhagat; other members of senior management team; and Strategic Growth Advisors, SGA, our Investor Relationship Advisor. We have uploaded our result, press release and investor presentation on the stock exchange and on company’s website. I hope everybody has had the opportunity to go through the same. The Indian Pharmaceutical Market, IPM, is witnessing one of its strongest growth phases. The IPM delivering sustainable double-digit monthly growth of over 10% since last December 2025. As per PharmaTrac, CORONA has continued to outperform the market, emerging as the fastest-growing pharmaceutical company amongst top 30 pharmaceutical companies. This strong performance has helped us improve our ranking by three positions over the past year, reaching from 29th to 26th position in IPM. We are pleased to report yet another strong quarterly performance in quarter 1 FY27 after listing, making our fourth consecutive quarter of robust growth. During the quarter, CORONA’s revenue grew by 21.9% year-on-year, surpassing our stated growth guidance of 15%. Our India business delivered an impressive 22.7% year-on-year revenue growth in quarter 1 FY27, significantly outperforming the Indian Pharmaceutical Market, which grew by 11.6% during the same period. This performance reflects growth at nearly twice the pace of IPM, underscoring the strength of our product portfolio, market execution and brand positioning. This sustained momentum reflects our disciplined execution, commitment to growth, reflection of our brand building and the continued trust that healthcare professionals place in our products. Most importantly, it reinforces our confidence in the strength and sustainability of our long-term growth strategy. Page 2 of 17 CORONA Remedies Limited August 03, 2026 Our growth during the quarter was broad-based, driven by the healthy product mix of volume growth, price growth and new introduction growth and continued brand building. As per PharmaTrac, in MAT June 2026, our volume growth stood 6.3%, significantly ahead of the IPM’s volume growth of 1.3%, which means we have grown in volume growth by 5x than the IPM. This reflects strong demand for our products among healthcare professionals and patients, driven by strength of our brands. We continue to build a portfolio of sustainable brands that deliver consistent market beating growth over the long term. Similarly, MAT June 2026 as per PharmaTrac, new product introduction continued approximately 3.4% to our growth compared to 2.9% of IPM. This is on the back of our ability to consistently launch relevant new products with strong market acceptance while leveraging our existing field force and relationship to drive effective cross- selling. Our price-led growth was approximately 8.7% compared to 5.6% of the IPM as per MAT June PharmaTrac data. This demonstrates the pricing power of our brands and our ability to implement price increases ahead of broader market, supported by sustained volume growth and strong brand equity. CORONA operates across four key therapeutic areas: Women’s Healthcare, Cardio-metabolic, Pain Management and Urology. We are pleased to share that we have established a strong leadership position across these focus therapies. We currently rank 5th in the Indian Pharmaceutical Market in both Women’s Healthcare and Pain Management, 9th in Urology, and 20th in the highly competitive Cardio-Diabeto segment, despite being a relatively late entrant. This achievement reflects our focus therapeutic strategy, differentiated marketing initiative and disciplined execution by our field force. Our performance across all four therapies continues to outpace the market. As per PharmaTrac, in Women’s Healthcare, we delivered a revenue growth of approximately 23.3%, nearly 2.5x the IPM growth of 9.4%. In Urology we grew 27.6% compared to the IPM of 14.9%. In Cardio-Diabeto and Pain Management, we outperformed the market by 1.7x and 1.4x respectively. Our strategy of focusing on middle of the pyramid, specialist segment has enabled us to deepen prescription share, strengthen relationship with healthcare professionals and build a portfolio of sustainable high-growth chronic brands. Our engine brand strategy continues to deliver strong results by consistently scaling up high- potential brands into meaningful growth platforms. As per PharmaTrac, in MAT June 2023, we had one brand with annual revenues exceeding INR100 crores. Today, we have two such brands and similarly, the number of brands gathering annual revenues of over INR10 crores has increased from 32 in MAT June 2023 to more than 40 brands in MAT June 2026. This scaling up of our brand portfolio reinforces the strength of our commercial model and gives us confidence in our ability to create many more enduring market-leading brands in years ahead. Page 3 of 17 CORONA Remedies Limited August 03, 2026 Speaking of specific highlights of quarter one FY27. During the qua [Showing first 8,000 characters — download PDF for full document]